Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Feature:   All Finviz Members Now Get Real-Time Earnings Data

Read More
Market News Market Pulse Stocks News ETF News Crypto News

Roivant Sciences

Contributing Author

Recent Articles by Roivant Sciences

Sep-23
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus ROIV GlobeNewswire
Sep-08
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study ROIV +18.75% GlobeNewswire
Sep-06
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call ROIV GlobeNewswire
Aug-27
Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. ROIV ROIV -7.64% GlobeNewswire
Aug-27
Priovant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. ROIV ROIV -7.64% GlobeNewswire
Aug-26
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Aug-06
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) ROIV GlobeNewswire
Aug-06
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update ROIV GlobeNewswire
Jul-23
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 ROIV GlobeNewswire
May-20
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update ROIV +14.89% GlobeNewswire
May-11
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 ROIV GlobeNewswire
Apr-02
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) ROIV GlobeNewswire
Apr-02
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) ROIV GlobeNewswire
Mar-28
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Mar-03
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna ROIV ROIV +6.00% GlobeNewswire
Mar-03
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis ROIV GlobeNewswire
Feb-06
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) ROIV +22.14% GlobeNewswire
Feb-06
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 ROIV +22.14% GlobeNewswire
Jan-23
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 ROIV GlobeNewswire
Dec-11
Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day ROIV +5.43% GlobeNewswire
Nov-10
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update ROIV GlobeNewswire
Oct-27
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 ROIV GlobeNewswire
Sep-17
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) ROIV +7.76% GlobeNewswire
Sep-11
Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List ROIV GlobeNewswire
Sep-03
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients ROIV GlobeNewswire
Aug-11
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update ROIV GlobeNewswire
Jul-28
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 ROIV GlobeNewswire
Jun-09
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis ROIV GlobeNewswire
May-29
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update ROIV +6.40% GlobeNewswire
May-15
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 ROIV GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)